title: Why denosumab obtains a survival benefit over zoledronic acid in bone metastatic lung cancer patients?
authors.forename: Laura
authors.initials: L
authors.lastname: Deiana
authors.forename: Melanie
authors.initials: M
authors.lastname: Claps
authors.forename: Alfredo
authors.initials: A
authors.lastname: Berruti
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000401:mortality*; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000401:mortality*; D008297:Male
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles